Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Phase 3 data expected in the second half of 2024
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Yesafili, received marketing authorization approval from the European Commission for the European Union
The company has raised US$4.5 million in funding for its AI operating system
The collaboration brings a seamless digital experience to more formulators worldwide
Subscribe To Our Newsletter & Stay Updated
